⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296571 | 0.65 | — | — | |
| SCHEMBL10296613 | 0.63 | — | — | |
| SCHEMBL12628156 | 0.56 | — | — | |
| SCHEMBL10296458 | 0.56 | — | — | |
| SCHEMBL3394653 | 0.56 | — | — | |
| SCHEMBL3392309 | 0.56 | — | — | |
| SCHEMBL7703054 | 0.55 | — | — | |
| SCHEMBL64855 | 0.55 | — | — | |
| SCHEMBL3224682 | 0.55 | — | — | |
| SCHEMBL1109961 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601664-A1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078745-A1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1601664-A1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078745-A1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |